IceCure Medical (NASDAQ: ICCM) awards CFO 181K stock units at $0

Rhea-AI Filing Summary

Peleg Meir reported acquisition or exercise transactions in this Form 4 filing.

IceCure Medical Ltd. reported that its Chief Financial Officer, Meir Peleg, received an equity compensation award. He was granted 181,483 restricted share units (RSUs) on August 14, 2026 at $0.00 per share-equivalent. According to the award terms, 25% of these RSUs vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter. The footnote also notes a prior grant of 13,333 RSUs on May 17, 2026 with the same 25%/75% quarterly vesting structure, and states that all of these RSUs remained unvested as of August 13, 2026. Following the new grant, Peleg’s reported holdings related to these awards total 194,816 ordinary share-equivalents, adjusted for a 1-for-30 reverse share split effected on June 4, 2026.

Insider Trade Summary

Net Buyer: 181,483 shares

Net Buy 1 txn

Insider Peleg Meir

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1	181,483	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 194,816 shares (Direct)

Footnotes (1)

1. F1. Represents (i) 181,483 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, and (ii) 13,333 RSUs granted on May 17, 2026, 25% of which vest on May 17, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter. All of the foregoing RSUs remain unvested as of August 13, 2026. The holdings described in clause (ii) has been adjusted to reflect the Issuer's 1-for-30 reverse share split effected on June 4, 2026.

Key Figures

New RSU grant: 181,483 RSUs RSU grant price: $0.00 per unit Post-grant reported holdings: 194,816 shares +4 more

7 metrics

New RSU grant 181,483 RSUs Restricted share units granted to CFO on August 14, 2026

RSU grant price $0.00 per unit Per-unit price for the 181,483 RSUs granted August 14, 2026

Post-grant reported holdings 194,816 shares Total ordinary share-equivalents reported following the August 14, 2026 grant

Prior RSU grant 13,333 RSUs RSUs granted May 17, 2026 with similar vesting terms

Initial vesting portion 25% Portion of each RSU grant vesting one year after the respective grant date

Quarterly vesting installments 12 installments of 6.25% Schedule for remaining 75% of each RSU grant

Reverse share split ratio 1-for-30 Reverse share split effective June 4, 2026 affecting reported RSU holdings

Key Terms

restricted share units ("RSUs"), reverse share split, vesting

3 terms

restricted share units ("RSUs") financial

"Represents (i) 181,483 restricted share units ("RSUs") granted on August 14, 2026"

reverse share split financial

"reflect the Issuer's 1-for-30 reverse share split effected on June 4, 2026"

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

vesting financial

"25% of which vest on August 11, 2027, and the remaining 75% vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What equity award did IceCure Medical (ICCM) CFO Meir Peleg receive on August 14, 2026?

IceCure Medical’s CFO Meir Peleg received a grant of 181,483 RSUs on August 14, 2026 at $0.00 per unit. These restricted share units vest partly after one year, then in twelve quarterly installments.

What is the vesting schedule for the new RSUs granted to ICCM’s CFO?

For the 181,483 RSUs granted August 14, 2026, 25% vest on August 11, 2027. The remaining 75% vest in twelve equal quarterly installments of 6.25% each following that initial vesting date.

How many RSUs in total are reported for ICCM’s CFO after the August 2026 grant?

After the August 14, 2026 grant, Meir Peleg’s reported holdings tied to these awards total 194,816 ordinary share-equivalents. This figure includes the new 181,483 RSUs plus a prior 13,333 RSU grant, adjusted for the reverse split.

Are the RSUs held by ICCM’s CFO vested as of August 13, 2026?

No, the disclosure states that all of the referenced RSUs remain unvested as of August 13, 2026. Both the May 17, 2026 and August 14, 2026 grants were still subject to their future vesting schedules at that time.

What prior RSU grant to ICCM’s CFO is referenced in this Form 4 filing?

The footnote references a prior grant of 13,333 RSUs on May 17, 2026. Like the newer award, 25% vest one year after grant and the remaining 75% vest in twelve quarterly 6.25% installments.

How did IceCure Medical’s reverse share split affect the CFO’s RSU holdings?

The holdings from the May 17, 2026 grant were adjusted for a 1-for-30 reverse share split effective June 4, 2026. The filing notes that the 13,333 RSUs figure reflects this share split adjustment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 08:16 AM Accepted by SEC EDGAR 08/17/2026 - 08:15 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peleg Meir

(Last) (First) (Middle)

7 HA'ESHEL ST., PO BOX 3163

(Street)

CAESAREA 3079504

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/14/2026		A		181,483	A	$0	194,816(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents (i) 181,483 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, and (ii) 13,333 RSUs granted on May 17, 2026, 25% of which vest on May 17, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter. All of the foregoing RSUs remain unvested as of August 13, 2026. The holdings described in clause (ii) has been adjusted to reflect the Issuer's 1-for-30 reverse share split effected on June 4, 2026.

	/s/ Meir Peleg	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)